Loading...
Market
UroGen Pharma partners with major pharmaceutical company by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Company press releases and major news outlets
Story
UroGen Pharma Stock Halted, Up 50% After 82.3% Response in Trial
Jun 13, 2024, 03:16 PM
UroGen Pharma's stock ($URGN) was halted after announcing unprecedented results from its ENVISION trial. The trial showed an 82.3% duration of response at 12 months for UGN-102, a potential first FDA-approved non-surgical treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Following the announcement, $URGN stock spiked 50%, with a trading volume of 5.5 million, 15 times the average daily volume.
View original story
Similar markets
Yes • 50%
No • 50%
No new partnerships • 33%
Partner with a major pharmaceutical company • 33%
Partner with multiple smaller pharmaceutical companies • 33%
No collaboration • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Partnership with Pfizer • 25%
Partnership with Johnson & Johnson • 25%
Partnership with Merck • 25%
No new partnership • 25%
